Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Tigers starter Olson leaves game against Royals after being struck by line drive
Why Blake Lively and Ryan Reynolds skipped the Met Gala for the SECOND year in a row
Lionel Messi's Inter Miami named the 18th
Jean Smart reveals Harry Styles' cheeky 'hack' for checking into hotels undercover
No more cute snaps of Mt Fuji. A screen is up in a Japanese town to prevent tourist crowds
Some Xavier University students upset with planned commencement address by UN ambassador
Nicaragua cancels a controversial Chinese interoceanic canal concession after nearly a decade
Moment Harry chuckles as he's asked 'are you happy to be home' during whistle
NASCAR star Kyle Larson is embracing his Indianapolis 500 debut, right down to milking a cow
Steve Albini, legendary producer and alternative rock pioneer, dies at 61
Fake elector case: Former Arizona GOP chair Kelli Ward and others set to be arraigned
Supreme Court Justice Neil Gorsuch co